- Home
- AMPY vs TCRX Comparison
AMPY vs TCRX Comparison
Compare AMPY & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMPY
- TCRX
- Stock Information
- Founded
- AMPY 2011
- TCRX 2018
- Country
- AMPY United States
- TCRX United States
- Employees
- AMPY N/A
- TCRX N/A
- Industry
- AMPY Oil & Gas Production
- TCRX Biotechnology: Pharmaceutical Preparations
- Sector
- AMPY Energy
- TCRX Health Care
- Exchange
- AMPY Nasdaq
- TCRX Nasdaq
- Market Cap
- AMPY 261.9M
- TCRX 285.5M
- IPO Year
- AMPY 2011
- TCRX 2021
- Fundamental
- Price
- AMPY $6.56
- TCRX $5.27
- Analyst Decision
- AMPY Strong Buy
- TCRX Strong Buy
- Analyst Count
- AMPY 3
- TCRX 5
- Target Price
- AMPY $10.00
- TCRX $11.40
- AVG Volume (30 Days)
- AMPY 275.3K
- TCRX 201.1K
- Earning Date
- AMPY 11-04-2024
- TCRX 11-07-2024
- Dividend Yield
- AMPY N/A
- TCRX N/A
- EPS Growth
- AMPY N/A
- TCRX N/A
- EPS
- AMPY 0.68
- TCRX N/A
- Revenue
- AMPY $311,557,000.00
- TCRX $12,200,000.00
- Revenue This Year
- AMPY $12.38
- TCRX N/A
- Revenue Next Year
- AMPY $3.41
- TCRX $3.10
- P/E Ratio
- AMPY $9.63
- TCRX N/A
- Revenue Growth
- AMPY 0.83
- TCRX N/A
- 52 Week Low
- AMPY $3.56
- TCRX $2.86
- 52 Week High
- AMPY $8.15
- TCRX $9.69
- Technical
- Relative Strength Index (RSI)
- AMPY 44.37
- TCRX 44.43
- Support Level
- AMPY $6.55
- TCRX $5.16
- Resistance Level
- AMPY $7.08
- TCRX $5.68
- Average True Range (ATR)
- AMPY 0.19
- TCRX 0.26
- MACD
- AMPY -0.04
- TCRX 0.01
- Stochastic Oscillator
- AMPY 7.56
- TCRX 57.29
About AMPY Amplify Energy Corp.
Amplify Energy Corp is an independent oil and natural gas company engaged in the acquisition, development, exploitation, and production of oil and natural gas properties in the United States. The company's oil and natural gas properties are located in large, mature oil and natural gas reservoirs. The company assets consists of producing oil and natural gas properties located in Oklahoma, the Rockies, federal waters offshore Southern California, East Texas/North Louisiana, and Eagle Ford.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.